BR112022003719A2 - Métodos para o tratamento de hiperfenilalaninemia - Google Patents
Métodos para o tratamento de hiperfenilalaninemiaInfo
- Publication number
- BR112022003719A2 BR112022003719A2 BR112022003719A BR112022003719A BR112022003719A2 BR 112022003719 A2 BR112022003719 A2 BR 112022003719A2 BR 112022003719 A BR112022003719 A BR 112022003719A BR 112022003719 A BR112022003719 A BR 112022003719A BR 112022003719 A2 BR112022003719 A2 BR 112022003719A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- hyperphenylalaninemia
- treatment
- sepiapterin
- phenylalanine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962905720P | 2019-09-25 | 2019-09-25 | |
| PCT/US2020/052871 WO2021062264A1 (en) | 2019-09-25 | 2020-09-25 | Methods for treating hyperphenylalaninemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022003719A2 true BR112022003719A2 (pt) | 2022-05-31 |
Family
ID=72827023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022003719A BR112022003719A2 (pt) | 2019-09-25 | 2020-09-25 | Métodos para o tratamento de hiperfenilalaninemia |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20220362249A1 (https=) |
| EP (1) | EP4034122B1 (https=) |
| JP (2) | JP7661315B2 (https=) |
| KR (1) | KR20220070477A (https=) |
| CN (1) | CN114650825A (https=) |
| BR (1) | BR112022003719A2 (https=) |
| CA (1) | CA3150003A1 (https=) |
| DK (1) | DK4034122T3 (https=) |
| ES (1) | ES3041002T3 (https=) |
| FI (1) | FI4034122T3 (https=) |
| HR (1) | HRP20251268T1 (https=) |
| HU (1) | HUE073483T2 (https=) |
| IL (1) | IL291565B1 (https=) |
| JO (1) | JOP20220042A1 (https=) |
| LT (1) | LT4034122T (https=) |
| MX (1) | MX2022003585A (https=) |
| PL (1) | PL4034122T3 (https=) |
| PT (1) | PT4034122T (https=) |
| RS (1) | RS67295B1 (https=) |
| SI (1) | SI4034122T1 (https=) |
| SM (1) | SMT202500493T1 (https=) |
| WO (1) | WO2021062264A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA46973A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Polymorphes de sépiaptérine et leurs sels |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| FI3801536T3 (fi) | 2018-05-30 | 2024-08-29 | Ptc Therapeutics Mp Inc | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi |
| EP3801534B1 (en) * | 2018-05-30 | 2026-02-18 | PTC Therapeutics MP, Inc. | Treatment of phenylketonuria with sepiapterin |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| ES2586945T3 (es) * | 2014-03-31 | 2016-10-19 | Vasopharm Gmbh | Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de dichas composiciones |
| MA46973A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Polymorphes de sépiaptérine et leurs sels |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| JP7811085B2 (ja) * | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| AU2019277372B2 (en) | 2018-05-30 | 2024-12-19 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
-
2020
- 2020-09-24 IL IL291565A patent/IL291565B1/en unknown
- 2020-09-25 HR HRP20251268TT patent/HRP20251268T1/hr unknown
- 2020-09-25 EP EP20789788.5A patent/EP4034122B1/en active Active
- 2020-09-25 SM SM20250493T patent/SMT202500493T1/it unknown
- 2020-09-25 PL PL20789788.5T patent/PL4034122T3/pl unknown
- 2020-09-25 US US17/764,003 patent/US20220362249A1/en active Pending
- 2020-09-25 SI SI202030677T patent/SI4034122T1/sl unknown
- 2020-09-25 RS RS20250917A patent/RS67295B1/sr unknown
- 2020-09-25 JP JP2022518780A patent/JP7661315B2/ja active Active
- 2020-09-25 CN CN202080067020.4A patent/CN114650825A/zh active Pending
- 2020-09-25 PT PT207897885T patent/PT4034122T/pt unknown
- 2020-09-25 HU HUE20789788A patent/HUE073483T2/hu unknown
- 2020-09-25 MX MX2022003585A patent/MX2022003585A/es unknown
- 2020-09-25 FI FIEP20789788.5T patent/FI4034122T3/fi active
- 2020-09-25 CA CA3150003A patent/CA3150003A1/en active Pending
- 2020-09-25 LT LTEPPCT/US2020/052871T patent/LT4034122T/lt unknown
- 2020-09-25 BR BR112022003719A patent/BR112022003719A2/pt unknown
- 2020-09-25 DK DK20789788.5T patent/DK4034122T3/da active
- 2020-09-25 ES ES20789788T patent/ES3041002T3/es active Active
- 2020-09-25 WO PCT/US2020/052871 patent/WO2021062264A1/en not_active Ceased
- 2020-09-25 KR KR1020227013671A patent/KR20220070477A/ko active Pending
-
2022
- 2022-02-22 JO JOP/2022/0042A patent/JOP20220042A1/ar unknown
-
2025
- 2025-04-02 JP JP2025061214A patent/JP2025111476A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SMT202500493T1 (it) | 2026-01-12 |
| SI4034122T1 (sl) | 2025-12-31 |
| IL291565B1 (en) | 2026-04-01 |
| AU2020353676A1 (en) | 2022-04-14 |
| HUE073483T2 (hu) | 2026-01-28 |
| FI4034122T3 (fi) | 2025-10-08 |
| IL291565A (en) | 2022-05-01 |
| CA3150003A1 (en) | 2021-04-01 |
| DK4034122T3 (da) | 2025-09-15 |
| LT4034122T (lt) | 2025-11-10 |
| JP2025111476A (ja) | 2025-07-30 |
| JP2022549834A (ja) | 2022-11-29 |
| JOP20220042A1 (ar) | 2023-01-30 |
| HRP20251268T1 (hr) | 2025-12-05 |
| PT4034122T (pt) | 2025-09-18 |
| WO2021062264A1 (en) | 2021-04-01 |
| MX2022003585A (es) | 2022-04-19 |
| CN114650825A (zh) | 2022-06-21 |
| EP4034122A1 (en) | 2022-08-03 |
| ES3041002T3 (en) | 2025-11-06 |
| JP7661315B2 (ja) | 2025-04-14 |
| US20220362249A1 (en) | 2022-11-17 |
| EP4034122B1 (en) | 2025-08-13 |
| RS67295B1 (sr) | 2025-11-28 |
| KR20220070477A (ko) | 2022-05-31 |
| PL4034122T3 (pl) | 2026-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022003719A2 (pt) | Métodos para o tratamento de hiperfenilalaninemia | |
| BR112019002730A2 (pt) | acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa | |
| BR112015001419A2 (pt) | composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios | |
| EA201990665A1 (ru) | Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака | |
| BR112022000231A2 (pt) | Novos métodos | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BR112022002609A2 (pt) | Métodos de tratamento de tumores estromais gastrointestinais | |
| BR112019008384A2 (pt) | composição farmacêutica, processos para tratamento e seus usos | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| BR112019004236A2 (pt) | compostos para tratar doenças associadas a uma disfunção mitocondrial | |
| BR112018070536A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| BR112018073553A2 (pt) | medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. | |
| BR112015030623A2 (pt) | agentes citotóxicos para o tratamento de câncer | |
| ATE543492T1 (de) | Behandlung von lungenkrebs | |
| EA035519B9 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака | |
| ZA201906327B (en) | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication | |
| BR112019005456A2 (pt) | composição farmacêutica e método para tratamento de esteatose hepática não alcoólica | |
| BR112018070514A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| BR112021020962A2 (pt) | Métodos de tratamento de prurido | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| BR112015012497A2 (pt) | combinações farmacêuticas | |
| MX380758B (es) | Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo. | |
| MX393807B (es) | Solucion de levodopa para infusion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |